See more : Kisses From Italy Inc. (KITL) Income Statement Analysis – Financial Results
Complete financial analysis of Axcella Health Inc. (AXLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axcella Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hochschild Mining plc (HCHDY) Income Statement Analysis – Financial Results
- Hybrid Kinetic Group Limited (FESTF) Income Statement Analysis – Financial Results
- SQI Diagnostics Inc. (SQD.V) Income Statement Analysis – Financial Results
- First Berlin Bancorp, Inc. (FTFI) Income Statement Analysis – Financial Results
- Rishi Laser Limited (RISHILASE.BO) Income Statement Analysis – Financial Results
Axcella Health Inc. (AXLA)
About Axcella Health Inc.
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.98M | 43.14M | 37.04M | 41.66M | 25.49M | 22.92M |
| General & Administrative | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Other Expenses | 0.00 | -4.00K | 10.00K | 34.00K | 0.00 | 0.00 |
| Operating Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Cost & Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Interest Income | 504.00K | 139.00K | 306.00K | 1.81M | 0.00 | 0.00 |
| Interest Expense | 3.02M | 2.92M | 3.01M | 3.40M | 0.00 | 0.00 |
| Depreciation & Amortization | 412.00K | 288.00K | 419.00K | 51.00K | 1.07M | 1.39M |
| EBITDA | -67.01M | -61.85M | -53.84M | -57.39M | -32.81M | -27.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.80M | -61.85M | -53.84M | -57.44M | -33.90M | -28.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.39M | -2.78M | -2.69M | -1.60M | -2.17M | -2.02M |
| Income Before Tax | -81.19M | -64.63M | -56.53M | -59.04M | -36.07M | -30.94M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.49M | 2.28M | 936.00K | -2.17M | 2.02M |
| Net Income | -81.19M | -67.12M | -58.81M | -59.97M | -36.07M | -30.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| EPS Diluted | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| Weighted Avg Shares Out | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
| Weighted Avg Shares Out (Dil) | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
3 Pharma Stocks to Dump Before the Damage Is Done
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Why Is Axcella Health (AXLA) Stock Down 24% Today?
Axcella Announces Reverse Stock Split Effective September 19, 2023
Why Is Axcella Health (AXLA) Stock Down 21% Today?
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Why Is Axcella Health (AXLA) Stock Up 280% Today?
Axcella Health stock rockets on long Covid patent win
Axcella Granted Patent for Long COVID Fatigue Treatment
Source: https://incomestatements.info
Category: Stock Reports